Peptide-Based Inhibitors for SARS-CoV-2 and SARS-CoV

Area of Science:

• Virology
• Drug Discovery
• Biochemistry

Background:

• The COVID-19 pandemic, caused by SARS-CoV-2, faces limited therapeutic options.
• Small molecules, particularly peptides, show potential due to their specificity and tunability.
• Understanding viral structure and entry mechanisms has spurred the development of entry inhibitors.

Purpose of the Study:

• To review SARS and SARS-CoV-2 inhibitors.
• To discuss therapeutic design, mechanisms, and targets.
• To highlight peptide therapeutics for viral inhibition.

Main Methods:

• Comprehensive literature review of viral inhibitors.
• Analysis of therapeutic strategies against SARS-CoV-2.
• Focus on peptide-based antiviral approaches.

Main Results:

• Peptide therapeutics demonstrate in vitro and in vivo efficacy against SARS-CoV-2.
• Peptides offer advantages in specificity, tunability, and adaptability to viral mutations.
• Various strategies for identifying viral inhibition targets are discussed.

Conclusions:

• Peptide therapeutics are a viable strategy for COVID-19 treatment.
• Targeting viral entry mechanisms with peptides is a key focus.
• Further research into peptide design and target identification is warranted.